Yervoy

BMS exits next-gen Yervoy pact, taking $300M in biobucks with it

Bristol Myers Squibb is walking away from CytomX's potential successor to Yervoy and wiping $300 million off the value of the alliance in the process.

Nick Paul Taylor Mar 12, 2024 7:07am

Ultimovacs links BMS-cancer vaccine combo to improved survival

Oct 18, 2023 8:40am

Long survival spurs Ultimovacs to mull ways to end cancer trial

Aug 22, 2023 10:00am

An artists impression of cancer cells The cancer cells are lavender on a yellow-gold background

PD-1 R&D tapers off as new molecules capture interest: IQVIA

May 24, 2023 2:09pm

Missed target failed trial trial failure

Jounce gets trounced as phase 2 data disappoint once again

Aug 31, 2022 7:30am

BMS melanoma, genitourinary commercial lead heads to miR

Aug 13, 2021 9:45am